… A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic … A. de Boer, Founder and CEO, will participate in the ADAR Editing Panel at the Chardan 7th Annual Genetic …
… for approximately 30 days following the presentation date. Download the presentation About Axiomer ® ProQR is pioneering … an endogenously expressed RNA editing system called ADAR, which can direct the change of an Adenosine (A) to an Inosine (I) in the RNA – an Inosine is …
… molecular machinery that is present in human cells called ADAR (Adenosine Deaminase Acting on RNA). Axiomer ® EONs are designed to recruit and direct endogenously expressed ADARs to change an Adenosine (A) to an Inosine (I) in the RNA …
About ProQR:ProQR Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in and Cambridge, Massachusetts, USA.
ProQR Therapeutics is a NASDAQ-listed biotechnology company headquartered in Leiden, the Netherlands with an office in and Cambridge, Massachusetts, USA.
… | New Orleans, Louisiana, USA Oral Presentation Title: ADAR-Mediated RNA Editing of SLC10A1(NTCP) as a Therapeutic … Editing-Based Correction of PNPLA3 I148M Functionality to Address Hepatic Steatosis (abstract 1654) Presenter: Gerard …
… Quarter 2025 Operating and Financial Results Axiomer™ ADAR-mediated RNA editing pipeline advancing across liver and CNS programs, with CTA filing on track for Q2 2025 for lead program AX-0810 targeting NTCP for Cholestatic diseases …
… Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development … Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell …
… we exclusively focused our strategy on RNA editing, ProQR made important progress with Axiomer, our ADAR-mediated RNA editing technology platform,” said Daniel … protein data with the liver target ANGPTL3 in mice. Additionally, we further strengthened our leading global IP …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
